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Background/Aims: The controlled attenuation parameter (CAP), based on tran-
sient elastography, is widely used for noninvasive assessment of the degree of 
hepatic steatosis (HS). We investigated the correlation of the degree HS between 
CAP and ultrasound (US) in patients with HS.
Methods: In total, 986 patients with US-based HS who underwent transient elas-
tography within 1 month were evaluated. The US-based grade of HS was catego-
rized as mild (grade 1), moderate (grade 2), or severe (grade 3).
Results: The CAP was significantly correlated with the US-based grade of HS (r = 
0.458, p < 0.001). The median CAP value of each US-based HS grade showed a pos-
itive correlation with grade (271.1, 303.7, and 326.7 dB/m for grades 1, 2, and 3). In a 
multivariate analysis, the US-based HS grade, body mass index, serum albumin, 
alanine aminotransferase, and total cholesterol, and liver stiffness were all sig-
nificantly correlated with the CAP value (all p < 0.05). The areas under the receiver 
operating characteristic curves for grade 2 to 3 and grade 3 HS were 0.749 (95% 
confidence interval [CI], 0.714 to 0.784) and 0.738 (95% CI, 0.704 to 0.772). The opti-
mal cut-off CAP values to maximize the sum of the sensitivity and specificity for 
grade 2 to 3 and grade 3 HS were 284.5 dB/m (sensitivity 78.6%, specificity 61.7%) 
and 298.5 dB/m (sensitivity 84.6%, specificity 55.6%).
Conclusions: The correlation of the degree of HS between CAP and US was sig-
nificantly high in patients with HS, and the optimal cut-off CAP values for grade 
2 to 3 and grade 3 HS were 284.5 and 298.5 dB/m.
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INTRODUCTION
Hepatic steatosis (HS) is the accumulation of triglycerides 
in the cytoplasm of hepatocytes [1-3]. HS is a major le-
sion of nonalcoholic fatty liver disease (NAFLD), which 
is the most common cause of chronic liver disease in 
Western countries [4]. In the past, the prevalence of NA-
FLD in Eastern countries was low. Recently, however, the 
prevalence of NAFLD has increased significantly in these 
regions with minimal differences compared with West-
ern countries [5]. Moreover, NAFLD is predicted to be the 
most frequent indication for liver transplantation by 2030 
[6]. HS can progress to steatohepatitis, fibrosis, cirrhosis, 
and hepatocellular carcinoma [7-9]. Therefore, the diag-
nosis of HS is important for both treatment and progno-
sis of the disease. 
To date, the gold standard for diagnosing and assess-
ing the severity of HS has been liver biopsy. However, 
biopsy has several limitations, such as invasiveness, in-
tra-observer and inter-observer variability, severe proce-
dure-related complications, and sampling error [10,11]. 
Ultrasound (US) is the liver-imaging technique used 
most frequently to detect steatosis. Despite its many ad-
vantages, the use of US has several drawbacks [3,12]. In a 
previous study, US had an overall sensitivity to steatosis 
of 84.8% but showed poor predictive power in certain 
groups [13]. For example, in morbidly obese patients, 
the sensitivity and specificity of US were only 49% and 
75%, and the prevalence of HS is underestimated in pa-
tients with less than 20% body fat [14,15]. Recently, the 
controlled attenuated parameter (CAP), a non-invasive 
quantitative method of measuring HS, has been devel-
oped to overcome these limitations [16,17]. It is easy to 
perform, does not require trained technicians as with 
US, and is less expensive compared with other tests. In 
addition, CAP is not affected by liver fibrosis or cirrhosis 
and is useful for quantifying and detecting HS in liv-
ers with greater than 10% fatty infiltration [18-21]. Com-
pared with liver biopsy, the areas under receiver operat-
ing characteristic curves (AUROCs) for using the CAP to 
measure ≥ 5%, > 33%, and > 66% steatosis were 0.79, 0.76, 
and 0.70 [22]. 
Currently, most research has focused on comparing 
the relative performances of liver biopsy and CAP, while 
studies examining the correlation between US and CAP 
are relatively rare. In this study, we investigated the cor-
relation of the degree of HS between CAP and US in pa-
tients with HS. 
METHODS
Study population
From April 2013 to August 2016, 986 patients who were 
diagnosed with US-based HS and subsequently under-
went transient elastography (TE) within 1 month in four 
Korean tertiary medical centers were enrolled. A total 
of 75 patients were excluded based on the following ex-
clusion criteria: (1) presence of hepatic malignancy; (2) 
unreliable TE results or TE assessment failure; (3) insuf-
ficient clinical data; and (4) other chronic liver diseases 
including viral hepatitis. Ultimately, 911 patients were 
evaluated retrospectively.
This study was performed in accordance with the 
ethical guidelines of the Declaration of Helsinki. In-
formed consent was not obtained, because de-identi-
fied data were analyzed. This study was approved by the 
Institutional Review Board of each participating hospi-
tal  (Soonchunhyang University Seoul Hospital, Num-
ber. 2016-08-033; Yonsei University Severance Hospital, 
Soonchunhyang University Bucheon Hospital, and Ko-
rea University Guro Hospital).
Ultrasound
Abdominal US were performed to assess HS, which 
was categorized as mild (grade 1), moderate (grade 2), or 
severe (grade 3) based on the following US features: (1) 
mild (grade 1), a slight increase in liver echogenicity; (2) 
moderate (grade 2), visualization of intrahepatic vessels, 
slightly impaired diaphragm, and increased liver echo-
genicity; and (3) severe (grade 3), a marked increase in 
hepatic echogenicity, poor penetration of the posterior 
segment of the right lobe of the liver, and poor or no vi-
sualization of the hepatic vessels and diaphragm [14,23].
Transient elastography
TE was performed by an experienced technician in each 
hospital. The evaluation was performed on the right 
lobe of the liver through the intercostal spaces on pa-
tients lying in the decubitus position with the right arm 
in abduction. The results are expressed as kilopascals 
(kPa) for liver stiffness (LS) and as dB/m for CAP. As 
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an indicator of variability, the ratio of the interquartile 
range (IQR) of the LS to the median was calculated. Only 
cases with at least 10 valid acquisitions, a success rate 
of at least 60%, and an IQR-to-median value ratio < 0.3 
were considered reliable and included in the statistical 
analysis. CAP was considered a valid value only when the 
LS for the same signal was reliable, using the same vol-
ume of liver parenchyma as in the LS.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation or median (IQR), whereas categorical variables 
are expressed as numbers (%). Univariate linear regres-
sion analyses were performed to identify the factors in-
fluencing CAP (age, body mass index, LS, US-based HS 
grade, and levels of aspartate aminotransferase, alanine 
aminotransferase [ALT], gamma glutamyl transferase, 
serum albumin, total bilirubin, and total cholesterol), 
followed by multivariate analysis of the factors with a 
p < 0.2 by univariate linear regression analysis. Spear-
man’s correlation coefficient was used to investigate 
the correlation between CAP and US-based HS grade. 
The performance of CAP for detecting the US-based HS 
grade was assessed using the AUROC. We calculated the 
cut-off values using the Youden index and calculated the 
sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV). A p < 0.05 was con-
sidered indicative of statistical significance. All analyses 
were performed using SPSS for Windows software ver-
sion 21.0 (IBM Co., Armonk, NY, USA).
RESULTS 
Baseline characteristics
The baseline characteristics of the 911 enrolled patients 
are shown in Table 1. The mean age of the patients was 
49.8 ± 13.9 years, and 64.5% were male. The mean body 
mass index (BMI) was 27.1 ± 4.2 kg/m2, and the mean ALT 
level was slightly elevated to 56.5 ± 43.2 U/L. The median 
LS value was 5.7 kPa (IQR, 4.4 to 7.6), and the median CAP 
value was 305 dB/m (IQR, 268 to 334). Regarding the US-
based HS grade, 303 (33.1%), 362 (40.9%), and 246 (26.9%) 
patients were grades 1, 2, and 3, respectively. 
Factors associated with CAP
Next, we performed a cross-sectional analysis to deter-
mine the baseline characteristics associated with the 
CAP score. In univariate linear regression analyses, the 
US-based HS grade (β = 23.4, p < 0.001), serum albumin 
level (β = 11.1, p = 0.010), BMI (β = 2.9, p < 0.001), LS (β 
= 0.8, p = 0.014), ALT level (β = 0.1, p = 0.019), and total 
cholesterol level (β = 0.1, p = 0.005) were associated with 
the CAP value (Table 2). In multivariate analysis, the US-
base HS grade (β = 23.7, p < 0.001) was a significant inde-
pendent factor associated with the CAP score, after ad-
justing for the serum albumin level (β = 12.0, p = 0.004), 
BMI (β = 3.1, p < 0.001), LS (β = 0.7, p = 0.022), ALT level 
(β = 0.1, p = 0.004), and total cholesterol level (β = 0.1, p = 
0.004) (Table 2). CAP scores increased by 23.4 dB/m for 
each increase in the HS grade determined by US. 
Correlation between CAP and US-based HS grade 
Next, we evaluated how well the CAP score was correlat-
ed with the US-based HS grade. As shown in Fig. 1, the 
CAP was significantly correlated with the US-based HS 
grade (ρ = 0.458, p < 0.001), and the median CAP value 
Table 1. Baseline characteristics of the patients (n = 911)
Variable Value
Age, yr, 49.8 ± 13.9
Male sex 591 (64.5)
Body mass index, kg/m2 27.1 ± 4.2
Serum albumin, g/dL 4.5 ± 0.4
Total bilirubin, mg/dL 0.8 ± 0.4
Aspartate aminotransferase, U/L 43.0 ± 32.6
Alanine aminotransferase, U/L 56.5 ± 43.2
Alkaline phosphatase, U/L 85.2 ± 62.2
Total cholesterol, mg/dL 192.5 ± 48.7




Liver stiffness, kPa 5.7 (4.4–7.6)
CAP, dB/m 305 (268–334)
Values are presented as mean ± SD, number (%), or median 
(interquartile range).
S1, mild steatosis; S2, moderate steatosis; S3, severe steatosis; 
CAP, controlled attenuation parameter. 
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for each US-based HS grade showed a positive dose-re-
sponse relationship. The median CAP values were 271.1, 
303.7, and 326.7 dB/m, for HS grades 1, 2, and 3, respec-
tively. 
Diagnostic performances of the CAP for fatty liver
Finally, we analyzed how well CAP values predict fatty 
liver. The AUROC values for the CAP and grade 2 to 3 
and grade 3 HS are shown in Fig. 2. Table 3 shows the 
diagnostic performance of CAP for assessing HS. The 
AUROC values for grade 2 to 3 and grade 3 HS were 0.749 
(95% confidence interval [CI], 0.714 to 0.784) and 0.738 
(95% CI, 0.704 to 0.772), respectively. The optimal cut-off 
CAP values for grade 2 to 3 and grade 3 HS were 284.5 and 
298.5 dB/m. The sensitivity, specificity, PPV, and NPV of 
CAP values of ≥ 284.5 and ≥ 298.5 dB/m for diagnosing 
grade 2 to 3 and grade 3 HS were 78.6%, 61.7%, 80.5%, 
and 59.0% and 84.6%, 55.6%, 41.4%, and 90.7%, respec-
tively. 
DISCUSSION
Among the many clinical tools available for diagnos-
ing fatty liver, US is the most commonly used [24,25]. 
In real-world practice, the frequency of using US for 
diagnosis or monitoring of NAFLD is approximately 
96% [10,11]. Previous studies have reported a correlation 
between liver biopsy and the CAP score, but liver biop-
sy is performed in less than 25% of NAFLD patients in 
clinical settings [10,11,24]. US is not only the most widely 
used clinical tool but also highly accurate in fatty liv-
er grading. As such, we investigated the correlation be-
tween US-assessed HS and the CAP value in a relatively 
large number of patients from multiple academic cen-
ters [26]. Because US and the CAP score are increasingly 
being utilized as non-invasive methods, the results of 
our study can be applied directly to clinical practice. 
Figure 1. Distribution of the controlled attenuation parame-
ter value according to ultrasound (US)-based hepatic steato-
sis grade. As the grade of steatosis increased, the controlled 














The grade of steatosis by US
Grade 1 Grade 2 Grade 3




β Standard error p value β Standard error p value
Age, yr –0.12 0.135 0.357
Body mass index, kg/m2 2.93 0.415 0.000 3.06 0.402 0.000
Liver stiffness, kPa 0.79 0.32 0.014 0.68 0.297 0.022
Ultrasound based hepatic steatosis grade 23.37 2.29 0.000 23.70 2.280 0.000
Total bilirubin, mg/dL –6.40 4.618 0.166
Aspartate aminotransferase, U/L 0.02 0.066 0.746
Alanine aminotransferase, U/L 0.12 0.052 0.019 0.11 0.038 0.004
Alkaline phosphatase, U/L –0.14 0.024 0.545
Serum albumin, g/dL 11.08 4.261 0.010 12.01 4.178 0.004
Total cholesterol, mg/dL 0.09 0.033 0.005 0.09 0.032 0.004
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We identified several factors associated with the CAP 
value. In a multivariate linear regression analysis, the 
US-based HS grade, serum albumin level, BMI, LS value, 
ALT level, and total cholesterol level were independent-
ly associated with the CAP score. Reported factors that 
are commonly associated with CAP scores include insu-
lin resistance indicators, e.g., levels of fasting C-peptide, 
fasting insulin, fasting glucose, glycated hemoglobin, 
and homeostasis model assessment of insulin resistance 
[27,28]. Furthermore, BMI and the total cholesterol level, 
which were found to be related in our study, are consid-
ered metabolic components that have been associated 
with the CAP score in many previous studies [9,21,29,30]. 
Although the serum albumin level has not been report-
ed previously in association with the CAP score, it can 
be interpreted as a reflection of nutritional parameters 
of the metabolic component. In fact, the serum albumin 
level was reported to be elevated in patients with NAFLD 
compared with normal populations [31]. 
In particular, the US-based HS grade was the most 
important parameter with a prominent β-coefficient. 
Ahn et al. [9] also reported that the correlation coeffi-
cient between US-assessed HS and the CAP value was ρ 
Table 3. Diagnostic performance of the controlled attenua-
tion parameter for detection of grade 2 to 3 and grade 3 he-
patic steatosis determined by ultrasound
Fatty liver grade Value
≥ Grade 2 steatosis
AUROC (95% CI) 0.749 (0.714–0.784)
CAP cut-off, dB/m 284.5
Sensitivity, % 78.6
Specificity, % 61.7
Positive predictive value, % 80.5
Negative predictive value, % 59.0
≥ Grade 3 steatosis
AUROC (95% CI) 0.738 (0.704–0.772)
CAP cut-off, dB/m 298.5
Sensitivity, % 84.6
Specificity, % 55.6
Positive predictive value, % 41.4
Negative predictive value, % 90.7
AUROC, area under the receiver operating characteristic 
curve; CI, confidence interval; CAP, controlled attenuation 
parameter.
Figure 2. Receiver operating characteristic curves and areas under the receiver operating characteristic curves (AUROC) of the 
controlled attenuation parameter (CAP) value to detect grade 2 to 3 and grade 3 ultrasound-based hepatic steatosis grade. The 
AUROCs for grade 2 to 3 (A) and grade 3 (B) ultrasound-based hepatic steatosis were 0.749 (95% confidence interval, 0.714 to 0.784) 
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= 0.580 (p < 0.001), which was consistent with our finding 
(ρ = 0.458, p < 0.001). In our study, the median CAP value 
for each HS grade also showed a positive dose-response 
relationship (grades 1 to 3: 271.1, 303.7, and 326.7 dB/m, 
respectively). CAP has been used to detect the degree 
of US beam attenuation by intracellular fat vacuoles at 
the center frequency of the probe [17]. Considering the 
principles of CAP, there appears to be a high correlation 
between the HS grade and CAP score.
To date, two studies have been published on the asso-
ciation between the CAP and HS grade. With respect to 
the diagnostic accuracy of the CAP, Ahn et al. [9] report-
ed AUROC values of 0.789 and 0.843 for grades 2 and 3 
steatosis, respectively. Yen et al. [32] also reported AU-
ROC values of 0.716 and 0.701 for moderate and severe 
steatosis, respectively, in NAFLD patients. Our study 
showed high accuracy for grade 2 to 3 (AUROC, 0.749) 
and grade 3 (AUROC, 0.738) steatosis. This supports oth-
er studies that showed a high accuracy of CAP in the 
evaluation of HS regardless of origin, including chronic 
viral hepatitis B and C, NAFLD, and alcoholic fatty liver 
disease [9,21].
In this study, the optimal cutoff values for grade 2 to 
3 and grade 3 HS were 284.5 and 298.5 dB/m, respective-
ly. Ferraioli et al. [33] reported that the mean CAP value 
for grade 2 was 265 dB/m. The optimal cut-off values for 
detection of grades 1, 2, and 3 HS were 238, 259, and 292 
dB/m, respectively, according to Sasso et al. [17] and 215, 
252, and 296 dB/m, respectively, according to de Leding-
hen et al. [34] Previous studies reported a difference of 
approximately 30 dB/m between grades 2 and 3 steatosis. 
Our study showed a difference between cut-off values 
of only 14 dB/m. We believe this difference in cut-off 
values can be attributed to the different characteristics 
of our study group compared with those of other stud-
ies. In our study, only NAFLD patients were analyzed. 
Moreover, the proportion of grade 3 patients was 26.9%, 
which is relatively high compared with previous studies. 
The populations of previous studies that reported the 
association between US and CAP consisted of less than 
20% grade 3 patients. Despite these differences in cut-off 
values, the sensitivities for grade 2 to 3 and grade 3 HS in 
our study were 78.6% and 84.6%, respectively. Therefore, 
more than 78% of patients with US-based moderate or 
severe HS were diagnosed using the CAP at these cut-off 
values. However, the specificity, PPV, and NPV of CAP 
values ≥ 284.5 and ≥ 298.5 dB/m in diagnosing grade 2 to 
3 and grade 3 HS were not high.
Our study has several limitations. First, unlike previ-
ous studies, the steatosis grade was calculated based on 
US and the CAP score rather than the liver biopsy-based 
steatosis grade. As such, our accuracy may have been 
compromised given that we were not using the current 
gold standard. However, as mentioned earlier, the use 
of US and CAP scores in the diagnosis of NAFLD is ex-
pected to exceed liver biopsy in the future, so there is 
a greater potential for future clinical applications. Sec-
ond, the limitations inherent to a cross-sectional design 
could not be avoided in this study, especially given the 
long-term prognosis of disease. 
In conclusion, our data showed that the CAP is rela-
tively well correlated with the degree of HS determined 
by US. The optimal cut-off CAP values for grade 2 to 3 
and grade 3 HS were 284.5 dB/m and 298.5 dB/m, with 
sensitivities of 78.6% and 84.6%, respectively. We believe 
that the CAP is useful for the diagnosis and grading of 
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KEY MESSAGE
1. We investigated the correlation between ultra-
sound (US) and the controlled attenuation param-
eter (CAP), two of the most popular non-invasive 
tools for the diagnosis of fatty liver. Our results 
show that the US-based grade of hepatic steatosis 
was significantly correlated with the CAP score 
after adjusting for other clinical factors.
2. The areas under the receiver operating charac-
teristic curves for grade 2 to 3 and grade 3 hepatic 
steatosis were 0.749 and 0.738, respectively. The 
optimal cut-off CAP value to maximize the sum of 
the sensitivity and specificity for grade 2 to 3 and 
grade 3 hepatic steatosis were 284.5 dB/m (sensitiv-
ity 78.6%, specificity 61.7%) and 298.5 dB/m (sensi-
tivity 84.6%, specificity 55.6%), respectively.
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